Dr. Sledge Defines the Term "Smart" Cancer

George W. Sledge, Jr., MD
Published: Monday, Apr 15, 2013

George W. Sledge, Jr, MD, Chief, Division of Oncology, Professor of Medicine, Stanford University School of Medicine, defines a "smart" cancer.

One end of the "smart" cancer spectrum contains many hematologic malignancies and childhood cancers, as they have few mutations. The other end of the spectrum, Sledge says, has colorectal cancer, melanoma, head and neck cancer, and lung cancer, as they have a large mutational load.

In the case of non-small cell lung cancer, a study showed that just three cigarettes caused a cancer mutation. This heavy load of mutations is what makes a cancer "smart."
 
George W. Sledge, Jr, MD, Chief, Division of Oncology, Professor of Medicine, Stanford University School of Medicine, defines a "smart" cancer.

One end of the "smart" cancer spectrum contains many hematologic malignancies and childhood cancers, as they have few mutations. The other end of the spectrum, Sledge says, has colorectal cancer, melanoma, head and neck cancer, and lung cancer, as they have a large mutational load.

In the case of non-small cell lung cancer, a study showed that just three cigarettes caused a cancer mutation. This heavy load of mutations is what makes a cancer "smart."
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x